GlaxoSmithKline: Human Genome Sciences Files BLA For Benlysta
10th Jun 2010 11:45
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a global pharmaceutical and healthcare company, said Thursday that Human Genome Sciences Inc. (HGSI) has submitted a Biologics License Application to the U.S. Food and Drug Administration, for Benlysta for reducing disease activity in adult patients
Read moreUPDATE: Wincanton Profit Falls But New Sectors To Aid Growth
10th Jun 2010 11:35
(Adds executive comment.) By Rachael Gormley and Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Haulier Wincanton PLC (WIN.LN) Thursday reported an 85% drop in fiscal year profit, hurt by a dip in revenue and a restructuring of its loss-making German operations, but said it is
Read moreUPDATE: NICE Blocks NHS Use Of Glaxo Drug Revolade
10th Jun 2010 09:28
(Adds comment from Glaxo.) By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--The U.K.'s National Institute for Health and Clinical Excellence, or NICE, Thursday said it won't recommend publicly-funded use of GlaxoSmithKline PLC's (GSK) Revolade drug for treatment of a rare blo
Read moreNICE Blocks NHS Use Of Glaxo Blood Platelet Booster Revolade
10th Jun 2010 01:01
LONDON (Dow Jones)--The U.K.'s National Institute for Health and Clinical Excellence, or NICE, Thursday said it won't recommend publicly-funded use of GlaxoSmithKline PLC's (GSK) Revolade drug for treatment of a rare blood clotting disorder that can cause dangerous bleeding, as the medicine is too e
Read moreUPDATE: UK Body Rejects State Funding For Glaxo's Tyverb Drug
9th Jun 2010 16:10
(Adds background and comment from Department of Health.) By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Britain's healthcare cost-effectiveness watchdog Wednesday said it could not approve publicly funded use of GlaxoSmithKline PLC's (GSK) oral breast cancer drug Tyverb, sayi
Read moreSOMETHING VENTURED: Biotechs Finally Making Progress On Lupus
9th Jun 2010 16:00
By Brian Gormley Of DOW JONES VENTUREWIRE The autoimmune disease lupus has bedeviled drug makers for a half century, but some are now poised to break through. Human Genome Sciences Inc. (HGSI) and GlaxoSmithKline PLC (GSK,GSK.LN) are set to seek regulatory approval for a drug they develop
Read moreUK Body Rejects State Funding For Glaxo's Tyverb Cancer Drug
9th Jun 2010 12:29
By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Britain's healthcare cost-effectiveness watchdog Thursday said it could not approve publicly-funded use of GlaxoSmithKline PLC's (GSK) oral breast cancer drug Tyverb, saying the medicine did not represent good value for money when c
Read moreWHO Head Defends Management Of Swine Flu Pandemic
8th Jun 2010 12:53
GENEVA (AFP)--The head of the World Health Organization Tuesday defended its handling of the A/H1N1 swine flu pandemic, rejecting a top medical journal claims that it was marred by commercial interests. "At no time, not for one second, did commercial interests enter my decision-making," said Mar
Read moreLondon midday: Decent morning for Footsie
18th May 2010 12:10
Footsie has made decent progress this morning helped by gains for utilities and the non-bank and insurance bits of the finance sector. Man Group is the best performer on reflection of yesterday's deal to buy GLG for $1.6bn. Inter-dealer broker ICAP is also in demand, while mezzanine finance lende
Read moreGSK signs strategic alliance with Dong-A
11th May 2010 07:56
Global pharmaceuticals leviathan GlaxoSmithKline has entered into a strategic alliance with South Korea's Dong-A Pharmaceuticals. As part of the deal, GSK will acquire a 9.9% minority stake in Dong-A, which has a portfolio of proprietary and generic pharmaceutical products and leading consumer heal
Read moreSunday tips round-up: GlaxoSmithKline, Brooks Macdonald, Gulfsands Petroleum
2nd May 2010 11:07
GlaxoSmithKline's first-quarter results showed strategic progress in the group's mission to move away from "white pill/western markets" to emerging economies and consumer products. The results were ahead of market expectations and showed good progress in its strategic plan. Trading on a December 2
Read moreBroker tips: Glaxo, Standard Life, Unilever
29th Apr 2010 12:35
Citigroup, UBS and Panmure Gordon remain buyers of GlaxoSmithKline (GSK) following the drug giant's first quarter numbers yesterday. Sales growth excluding the boost from swine-flu related drugs was 4%, two percentage points ahead of consensus, Citi said. The broker, which keeps its 'buy' rating a
Read moreBroker snap: Glaxo numbers well-received
29th Apr 2010 09:38
Citigroup, UBS and Panmure Gordon remain buyers of GlaxoSmithKline following the drug giant's first quarter numbers yesterday. Sales growth excluding the boost from swine-flu related drugs was 4%, 2 percentage points ahead of consensus, Citi said. The broker, which keeps its 'buy' rating and 1,375
Read moreLondon close: S&P puts spanner in the works
28th Apr 2010 17:09
For the second day in a row the debt ratings agency Standard & Poor's has sent markets into a late swoon, this time with a downgrade on Spanish sovereign debt. Standard & Poor's (S&P) cut its long-term sovereign credit rating on Spain, saying the country is likely to see an extended period of subd
Read moreLondon afternoon: Footsie in positive territory
28th Apr 2010 14:40
The FTSE 100 is now in positive territory as heavily weighted index constituents such as Shell, BP, HSBC and Glaxo make headway, but the FTSE 250 index remains in the red. Higher oil prices helped Royal Dutch Shell post a sharp rise in earnings in the first quarter of 2010. Profit jumped to $4.9bn
Read more